logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
P

Peter J. Goebell

free university of berlin
H指数:25
被引数:3,000

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04研究的通俗语言摘要：沙西妥珠单抗在铂类化疗和免疫疗法之后，用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群

FUTURE ONCOLOGY
IF2.6
2025-11-011
PRE
Powles, Thomas; Tagawa, Scott T.; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N.; Bellmunt, Joaquim; Goebell, Peter J.; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S.; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT

TKI和CPI一线治疗策略在晚期肾细胞癌中的头对头比较——来自德国研究平台CARAT的真实世界数据

INTERNATIONAL JOURNAL OF CANCER
IF4.7
2025-10-010
OAAI
Goebell, Peter J.; Bogemann, Martin; Nusch, Arnd; Grunwald, Viktor; Muller, Lothar; Von Der Heyde, Eyck; Martens, Uwe M.; Lennartz, Carolin; Koska, Michaela; Potthoff, Karin; Kaiser-Osterhues, Anja; Grullich, Carsten; Staehler, Michael; Janicke, Martina; Marschner, Dominik
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

非透明细胞肾细胞癌中，伊匹木单抗/纳武利尤单抗对比标准护理的 prospective randomized phase-II trial - SUNNIFORECAST trial 的结果

Annals of Oncology
IF65.4
2025-04-010
OA
L. Bergmann; L. Albiges; M. Ahrens; M. Gross-Goupil; E. Boleti; G. Gravis; A. Fléchon; M.-O. Grimm; J. Bedke; P. Barthélémy; D. Castellano; B. Mellado; P. Ivanyi; S. Rottey; A. Flörcken; C. Suarez; P. Maroto; V. Grünwald; S.F. Oosting; J. Kopecky; S. Zschäbitz; M. Boegemann; T. Buchler; G. Niegisch; P.J. Goebell; T. Waddell; F. Joly; F. Priou; M. Retz; S. Siemer; U. Zimmermann; D. Deckbar; I. Burkholder; A. Hartmann; J.B. Haanen
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Sacituzumab govitecan在晚期尿路上皮癌中的应用：TROPiCS-04，一项III期随机试验

ANNALS OF ONCOLOGY
IF65.4
2025-02-014
PRE
Powles, T.; Tagawa, S.; Vulsteke, C.; Gross-Goupil, M.; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales-Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Kovalenko, M.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C. S.; Waldes, J.; Loriot, Y.; Grivas, P.
TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis

TROPiCS-04，一项关于sacituzumab govitecan（SG）与化疗（CT）对比治疗经治晚期尿路上皮癌（aUC）的随机III期研究：总生存期（OS）和安全性的分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Grivas, P.; Powles, T. B.; Vulsteke, C.; Goupil, M. Gross; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C.; Waldes, J.; Tagawa, S. T.; Loriot, Y.
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials
EUROPEAN UROLOGY
IF25.2
2022-01-0168
OA
Burdett, Sarah; Fisher, D. J.; Vale, C. L.; Tierney, J. F.; Clarke, N. W.; Parmar, M. K. B.; Sternberg, C. N.; Stoeckle, M.; Lehmann, J.; Studer, U. E.; Sonntag, R. W.; Torti, F. M.; Groshen, S.; Bono, A. V.; Goebell, P. J.; Cognetti, F.; Cote, R. J.; Groshen, S.; Collette, L.; Sternberg, C. N.; Rolevich, A. I.; Zhegalik, A. G.

研究方向

暂未获取到该数据
B
Bernd Wullich
H 指数:62论文数:610被引数:4.4万
A
Arndt Hartmann
H 指数:97论文数:2,397被引数:4.5万
M
Michael Staehler
H 指数:65论文数:486被引数:2.2万
H
Helge Täubert
H 指数:63论文数:465被引数:4.7万
V
Viktor Grünwald
H 指数:56论文数:641被引数:1.9万
C
Christian Schmidkonz
H 指数:21论文数:101被引数:1,753
T
Torsten Kuwert
H 指数:59论文数:446被引数:1.2万
S
Sven Wach
H 指数:54论文数:285被引数:4.2万
P
Philipp Ritt
H 指数:22论文数:123被引数:1,948
M
Michael Uder
H 指数:65论文数:1,032被引数:1.9万